Weight and Metabolic Changes After Switching From Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) plus Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC plus DTG, and TDF/FTC/Efavirenz (EFV) to TDF/Lamivudine (3TC)/DTG

被引：45

作者：

Bosch, Bronwyn ^{[1
]}

Akpomiemie, Godspower ^{[1
]}

Chandiwana, Nomathemba ^{[1
]}

Sokhela, Simiso ^{[1
]}

Hill, Andrew ^{[2
]}

McCann, Kaitlyn ^{[3
]}

Qavi, Ambar ^{[3
]}

Mirchandani, Manya ^{[3
,4
]}

Venter, Willem Daniel Francois ^{[1
]}

机构：

[1] Univ Witwatersrand, Fac Hlth Sci, Ezintsha, Johannesburg, South Africa

[2] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool, Lancashire, England

[3] Imperial Coll, Fac Med, London, England

[4] Imperial Coll London, Exhibit Rd, South Kensington, London SW7 2BX, England

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 08期

基金：

英国医学研究理事会; 美国国家卫生研究院;

关键词：

tenofovir alafenamide; efavirenz; dolutegravir; body weight; HIV;

D O I：

10.1093/cid/ciac949

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin.

引用

页码：1492 / 1495

页数：4

共 12 条

[1] CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz [J].

Griesel, Rulan ;

Maartens, Gary ;

Chirehwa, Maxwell ;

Sokhela, Simiso ;

Akpomiemie, Godspower ;

Moorhouse, Michelle ;

Venter, Francois ;

Sinxadi, Phumla .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) :E3902-E3909

[2] Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain [J].

Kauppinen, Kai Juhani ;

Aho, Inka ;

Sutinen, Jussi .

AIDS, 2022, 36 (10) :1337-1344

[3] Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes [J].

McCann, Kaitlyn ;

Shah, Shahini ;

Hindley, Laura ;

Hill, Andrew ;

Qavi, Ambar ;

Simmons, Bryony ;

Serenata, Celicia ;

Sokhela, Simiso ;

Venter, Willem D. F. .

AIDS, 2021, 35 (10) :1657-1665

[4]

MILINKOVIC A, 2019, AIDS, V33, P2387, DOI DOI 10.1097/QAD.0000000000002350

[5] Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials [J].

Pilkington, Victoria ;

Hughes, Sophie L. ;

Pepperrell, Toby ;

McCann, Kaitlyn ;

Gotham, Dzintars ;

Pozniak, Anton L. ;

Hill, Andrew .

AIDS, 2020, 34 (15) :2259-2268

[6] Is tenofovir disoproxil fumarate associated with weight loss? [J].

Shah, Shahini ;

Pilkington, Victoria ;

Hill, Andrew .

AIDS, 2021, 35 :S189-S195

[7] Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations [J].

Sinxadi, Phumla Zuleika ;

McIlleron, Helen Margaret ;

Dave, Joel Alex ;

Smith, Peter John ;

Levitt, Naomi Sharlene ;

Haas, David William ;

Maartens, Gary .

MEDICINE, 2016, 95 (02) :1-7

[8] Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study [J].

Surial, Bernard ;

Ledergerber, Bruno ;

Calmy, Alexandra ;

Cavassini, Matthias ;

Gunthard, Huldrych F. ;

Kovari, Helen ;

Stockle, Marcel ;

Bernasconi, Enos ;

Schmid, Patrick ;

Fux, Christoph A. ;

Furrer, Hansjakob ;

Rauch, Andri ;

Wandeler, Gilles .

JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (04) :637-645

[9]

Venter WF., 2022, 24 INT AIDS C MONTRE

[10]

Venter WDF, 2020, LANCET HIV, V7, pE666, DOI 10.1016/S2352-3018(20)30241-1

← 1 2 →